Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

BIOMARIN PHARMACEUTICAL INC Form 4 November 22, 2006

November 22	2, 2006											
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION									OMB APPROVAL			
Check thi	Check this box									Number:	3235-0287	
if no long subject to Section 1 Form 4 or	ger STATEN 6.										January 31, 2005 verage rs per 0.5	
Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 1(b).												
(Print or Type F	Responses)											
1. Name and Address of Reporting Person <u>*</u> KAKKIS EMIL D			2. Issuer Name and Ticker or Trading Symbol BIOMARIN PHARMACEUTICAL					-	5. Relationship of Reporting Person(s) to Issuer			
	INC [BMRN]						(Check all applicable)					
(Last)	3. Date of Earliest Transaction (Month/Day/Year)						Director 10% Owner X Officer (give title Other (specify below) below)					
C/O BIOMA PHARMAC DIGITAL D	EUTICAL INC.,	105	10/31/20)06					Chief	Medical Office	r	
	(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person					
NOVATO, O	CA 94949								Form filed by M Person	ore than One Re	porting	
(City)	(State)	(Zip)	Tabl	e I - No	on-D	erivative	Secur	ities Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)			Code (Instr. 3, 4 and 5)					Securities Beneficially Owned Following	OwnershipInForm: DirectB(D) orOIndirect (I)(I	Ownership		
				Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)	(Instr. 4)		
Common Stock	10/31/2006(1)			Р	V	4,368	А	\$ 3.434	38,144	D		
Common Stock									3,000	I	Shares held by spouse.	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of onDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration Date		7. Title and Amount Underlying Securitie (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amou Numb Shares
Stock Option (right to buy)	\$ 17.54	11/20/2006		А	100,000	05/20/2007 <u>(2)</u>	11/19/2016	Common Stock	100,0

Reporting Owners

Reporting Owner Name / Address		Relationships						
	1	Director	10% Owner	Officer	Other			
KAKKIS EMIL D C/O BIOMARIN PHARMACEUTICA 105 DIGITAL DRIVE NOVATO, CA 94949	L INC.			Chief Medical Officer				
Signatures								
/s/ G. Eric Davis, Attorney-in-Fact	11/22/20	06						

Date

<u>**</u>Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Purchase made pursuant to Employee Stock Purchase Plan.
- (2) Options vest 6/48th on May 20, 2007 and 1/48th on the 20th of each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.